OraSure misses Q3 revenue estimates

OraSure Technologies

05/11/2025 22:06

Overview

OraSure Q3 revenue declines 32% yr/yr, missing analyst expectations

Adjusted operating income for Q3 beats analyst estimates

Company repurchased 1.5 mln shares for $5 mln in Q3

Outlook

Company guides Q4 2025 revenues between $25 mln and $28 mln

OraSure plans new product launches in rapid diagnostics and sample management solutions in 2026

Company sees strong balance sheet aiding navigation of short-term turbulence

Result Drivers

FUNDING UNCERTAINTY - Co says some customers face uncertainty in funding for public health programs, impacting core business revenues

PRODUCT LAUNCHES - Co expects growth from new product launches in rapid diagnostics and sample management solutions next year

DECLINE IN HIV TEST REVENUE - Diagnostics revenues decreased 34% yr/yr due to lower revenue from HIV tests

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$27.10 mln
$29.13 mln (3 Analysts)
Q3 Gross Margin
43.50%
Q3 Adjusted Operating Income
Beat
-$12.70 mln
-$18.05 mln (2 Analysts)
Q3 Operating Income
-$16.10 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

Wall Street's median 12-month price target for OraSure Technologies Inc is $4.75, about 45.9% above its November 4 closing price of $2.57

Press Release: ID:nGNX5s5HCg

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)